Fri0174 Subcutaneous Dosing of the Novel Anti-cd40 Antibody Iscalimab Achieves Target Drug Exposure and Clinical Efficacy in Primary Sjögren's Syndrome; Results of a Phase Iia Randomised Open Label Two Arm Parallel Group Trial
Year: 2019
Type: conference-abstract
Source: Annals of the Rheumatic Diseases
Authors: Benjamin Fisher, Antónia Szántó, Wan Fai Ng, Michele Bombardieri, Maximilian Posch, Athena Papas, Arwa Farag, Thomas Daikeler, Bettina Bannert, Alan Kivitz, Steven Carsons, David Isenberg, Francesca Barone, Simon J. Bowman, Pascal Espie, Grazyna Wieczorek, Pierre Moulin, David Floch, Cyrielle Dupuy, Amanda Nguyen, Andrew Wright, Michael Rotte, James Rush, Peter Gergely
Institutions: University of Birmingham, University of Debrecen, Newcastle University, Queen Mary University of London, Tufts University, University Hospital of Basel, Altoona Center for Clinical Research, Winthrop-University Hospital, New York University, University College Hospital, Novartis Institutes for BioMedical Research, Novartis (Switzerland)
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: GlaxoSmithKline
Awards: G1374170088, G2373788206
OpenAlex ID: W2950270461